# Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company): Phase 2 study completed, 280 enrolled (Inflammatory Bowel Diseases, Colitis, Ulcerative)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC |
| NCT ID | NCT05611671 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Inflammatory Bowel Diseases; Colitis, Ulcerative |
| Intervention types | drug |
| Target enrollment | 280 |
| Site countries | United States, Australia, Austria, Bulgaria, Czechia, Estonia, France, Georgia, Germany, Hungary, India, Israel |
| Posted | 2022-11-10 |
| Planned start | 2022-11-21 |
| Event | Completed |
| Event date | 2026-09-21 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 280 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05611671). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.